Arcus Biosciences, Inc.
RCUS
$22.43
$0.220.99%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -106.00M | -135.00M | 0.00 | -112.00M | -94.00M |
| Total Depreciation and Amortization | 3.00M | 2.00M | 2.00M | 3.00M | 3.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.00M | 15.00M | 13.00M | 14.00M | 14.00M |
| Change in Net Operating Assets | -30.00M | 21.00M | -148.00M | -37.00M | -23.00M |
| Cash from Operations | -120.00M | -97.00M | -133.00M | -132.00M | -100.00M |
| Capital Expenditure | -1.00M | 0.00 | 0.00 | -1.00M | -1.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -181.00M | 79.00M | 137.00M | 33.00M | 52.00M |
| Cash from Investing | -182.00M | 79.00M | 137.00M | 32.00M | 51.00M |
| Total Debt Issued | 0.00 | 0.00 | 49.00M | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 286.00M | 8.00M | 3.00M | 142.00M | 3.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -5.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 286.00M | 8.00M | 52.00M | 142.00M | -2.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.00M | -10.00M | 56.00M | 42.00M | -51.00M |